Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers-New Jersey Medical School, Newark, NJ 07103, United States.
Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Harborview Medical Center, Seattle, WA 98104, United States.
Vaccine. 2019 Mar 22;37(13):1807-1818. doi: 10.1016/j.vaccine.2019.02.022. Epub 2019 Feb 20.
Syphilis is resurgent in many developed countries and still prevalent in developing nations. Current and future control campaigns would benefit from the development of a vaccine, but although promising vaccine candidates were identified among the putative surface-exposed integral outer membrane proteins of the syphilis spirochete, immunization experiments in the rabbit model using recombinant antigens have failed to fully protect animals upon infectious challenge. We speculated that such recombinant immunogens, purified under denaturing conditions from Escherichia coli prior to immunization might not necessarily harbor their original structure, and hypothesized that enhanced protection would result from performing similar immunization/challenge experiments with native antigens.
To test our hypothesis, we engineered non-infectious Borrelia burgdorferi strains to express the tp0897 (tprK) and tp0435 genes of Treponema pallidum subsp. pallidum and immunized two groups of rabbits by injecting recombinant strains intramuscularly with no adjuvant. TprK is a putative integral outer membrane protein of the syphilis agent, while tp0435 encodes the highly immunogenic T. pallidum 17-kDa lipoprotein, a periplasmic antigen that was also shown on the pathogen surface. Following development of a specific host immune response to these antigens as the result of immunization, animals were challenged by intradermal inoculation of T. pallidum. Cutaneous lesion development was monitored and treponemal burden within lesions were assessed by dark-field microscopy and RT-qPCR, in comparison to control rabbits.
Partial protection was observed in rabbits immunized with B. burgdorferi expressing TprK while immunity to Tp0435 was not protective. Analysis of the humoral response to TprK antigen suggested reactivity to conformational epitopes.
Immunization with native antigens might not be sufficient to obtain complete protection to infection. Nonetheless we showed that non-infectious B. burgdorferi can be an effective carrier to deliver and elicit a specific host response to T. pallidum antigens to assess the efficacy of syphilis vaccine candidates.
梅毒在许多发达国家死灰复燃,在发展中国家仍然流行。当前和未来的控制活动将受益于疫苗的开发,但尽管在梅毒螺旋体的假定表面暴露的整合外膜蛋白中鉴定出有前途的疫苗候选物,但使用重组抗原在兔模型中的免疫实验未能在感染性挑战时完全保护动物。我们推测,在免疫之前,在变性条件下从大肠杆菌中纯化的此类重组免疫原可能不一定具有其原始结构,并假设使用天然抗原进行类似的免疫/挑战实验会产生增强的保护作用。
为了检验我们的假设,我们设计了非感染性的伯氏疏螺旋体菌株来表达梅毒亚种的 tp0897(tprK)和 tp0435 基因,并通过肌肉内注射重组菌株来免疫两组兔子,没有佐剂。TprK 是梅毒剂的假定整合外膜蛋白,而 tp0435 编码高度免疫原性的梅毒 17-kDa 脂蛋白,这是一种周质抗原,也存在于病原体表面。在免疫这些抗原后,宿主产生了特异性的免疫反应,然后通过皮内接种梅毒螺旋体对动物进行了挑战。通过暗场显微镜和 RT-qPCR 监测皮肤损伤的发展,并评估病变内的梅毒螺旋体负担,与对照兔子进行比较。
在免疫表达 TprK 的伯氏疏螺旋体的兔子中观察到部分保护,而对 Tp0435 的免疫则没有保护作用。对 TprK 抗原的体液反应分析表明其对构象表位有反应。
用天然抗原免疫可能不足以获得对感染的完全保护。尽管如此,我们表明非感染性的伯氏疏螺旋体可以作为一种有效的载体来传递和引起针对梅毒螺旋体抗原的特异性宿主反应,以评估梅毒疫苗候选物的功效。